397 related articles for article (PubMed ID: 25936301)
1. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
Gouni-Berthold I; Berthold HK
Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
[TBL] [Abstract][Full Text] [Related]
2. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
Rader DJ; Kastelein JJ
Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
[No Abstract] [Full Text] [Related]
3. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
Won JI; Zhang J; Tecson KM; McCullough PA
Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
[TBL] [Abstract][Full Text] [Related]
4. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
[TBL] [Abstract][Full Text] [Related]
5. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
6. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
[TBL] [Abstract][Full Text] [Related]
7. Lomitapide for the management of homozygous familial hypercholesterolemia.
deGoma EM
Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
[TBL] [Abstract][Full Text] [Related]
8. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
9. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.
Toth PP; Shah PK; Wilkinson MJ; Davidson MH; McCullough PA
Rev Cardiovasc Med; 2014; 15(1):1-10. PubMed ID: 24762461
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.
Vuorio A; Tikkanen MJ; Kovanen PT
Vasc Health Risk Manag; 2014; 10():263-70. PubMed ID: 24851052
[TBL] [Abstract][Full Text] [Related]
11. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
Marbach JA; McKeon JL; Ross JL; Duffy D
Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
[TBL] [Abstract][Full Text] [Related]
12. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
[TBL] [Abstract][Full Text] [Related]
13. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
Perry CM
Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
[TBL] [Abstract][Full Text] [Related]
14. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
15. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
Cuchel M; Blom DJ; Averna MR
Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
[TBL] [Abstract][Full Text] [Related]
17. Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.
Averna M; Cefalù AB; Stefanutti C; Di Giacomo S; Sirtori CR; Vigna G
Nutr Metab Cardiovasc Dis; 2016 Jan; 26(1):36-44. PubMed ID: 26723464
[TBL] [Abstract][Full Text] [Related]
18. Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.
Sirtori CR; Pavanello C; Bertolini S
Ann Med; 2014 Nov; 46(7):464-74. PubMed ID: 24987866
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
Marbach JA; Thapa J; Goldenberg E; Duffy D
Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926
[TBL] [Abstract][Full Text] [Related]
20. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
